Lunsumio (Mosunetuzumab-axgb)
- Medicine Name: Lunsumio
- Generic Name: Mosunetuzumab-axgb
- Dosage Form & Strength: Injection: 1 mg/mL and 30 mg/30 mL
- Manufactured By: Genentech, Inc.
Medical Uses
Lunsumio (mosunetuzumab-axgb) is a bispecific CD20-directed CD3 T-cell engager used to treat adult patients with relapsed or refractory follicular lymphoma after a couple of or multiple lines of systemic therapy.
Note: The conditional approval is based on the response rate. Studies are going on to establish how well the medicine works.
Recommended Dosage: Premedicate prior to each dose in Cycle 1 and 2 to reduce the risk of cytokine release syndrome (CRS) and infusion-related reactions. Administer only as an intravenous (IV) infusion. Each cycle is 21 days. The recommended dosage regimen of Lunsumio is as follows:
- Cycle 1 (Day 1): 1 mg administered intravenously over at least 4 hours.
- Cycle 1 (Day 8): 2 mg administered intravenously over at least 4 hours.
- Cycle 1 (Day 15): 60 mg administered intravenously over at least 4 hours.
- Cycle 2 (Day 1): 60 mg administered intravenously over 2 hours if infusion in Cycle 1 was well-tolerated
- Cycle 3 and subsequent cycles (Day 1): 30 mg administered intravenously over 2 hours if infusion in Cycle 1 was well-tolerated
Continue for 8 cycles, unless respective patients experience unacceptable toxicity or disease progression. For those who reach a complete response, no further treatment of more than 8 cycles is required. For those who reach a partial response or have stable disease in response following 8 cycles, an additional 9 cycles (total 17 cycles) need to be given, unless a patient experiences any unacceptable toxicity or in case of disease progression.
Warning & Precautions
- Lunsumio treatment can cause cytokine release syndrome (CRS), including serious or hazardous reactions. Those who experience CRS (or other side effects that impair consciousness) should be assessed and instructed not to drive and to refrain from operating machinery until resolution.
- Therapy with mosunetuzumab can cause serious neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Assess patients for neurologic toxicity during treatment. At the initial sign of neurologic toxicity, including ICANS, promptly assess the patient, and consider neurology assessment as required.
- Lunsumio 1 mg/30 mg can be responsible for causing severe or fatal infections. Monitor patients for signs and symptoms of infection before and throughout the treatment and treat effectively. It should not be used in the presence of current or active infection.
- Lunsumio injection can be responsible for causing severe or critical cytopenias, including anemia, neutropenia, and thrombocytopenia. Monitor complete blood counts (CBC) throughout therapy. On behalf of the severity of cytopenias, temporarily interrupt, or permanently stop treatment.
- Lunsumio can cause critical tumor flare. All those with bulky tumors located in near proximity to airways or a vital organ need to be monitored precisely during the first therapy. Monitor patients for compression or obstruction because of mass effect secondary to tumor flare.
- As per the mechanism of action, this drug may cause fetal harm if administered to a pregnant woman. Females of reproductive age/potential should use suitable contraception ways during treatment and for 3 months following the last dose.
Documentation & Availability
What documents are required to import LUNSUMIO to India?
LUNSUMIO (mosunetuzumab-axgb) injection can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients ID proof (issued by the government of India)
How does the order be confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from Doctor
- Import permit if applicable
Is LUNSUMIO available in India?
LUNSUMIO (mosunetuzumab-axgb injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). S S Healthcare is the facilitator providing input
- On availability of Lunsumio in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
Ensuring 100% transparency.
LUNSUMIO can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
S S Healthcare (S S Healthcare) can facilitate the supply of LUNSUMIO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-7575883015 | Toll-Free Number: +91-7575883015 or write us at sshealthcare1012@gmail.com for Lunsumio 1 mg/30 mg price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
S S Healthcare is able to source the LUNSUMIO (Cancer Treatment Medicines) from across the globe and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Lunsumio®?
Mosunetuzumab-axgb is a Generic Name for the trade name drug Lunsumio®.
What is the Manufacturer’s Name of Lunsumio®?
Lunsumio® is manufactured by Genentech, Inc.
Is Lunsumio® approved by the FDA?
Yes, Lunsumio® is approved by the FDA. Date of approval: December 22, 2022.
Where can I get Lunsumio® at the best price in India?
To get the best Lunsumio price in India, kindly connect with the S S Healthcare (a WHO GDP & ISO 9001:2008 certified company). For Lunsumio®, a medical prescription is required from a treating physician.
What is the dosage and form of Lunsumio® supplied?
Lunsumio® is supplied as Injections: 1 mg/mL and 30 mg/30 mL (1 mg/mL) solution in a single-dose vial for intravenous administration.
What are the most common side effects of Lunsumio®?
The most common side effects of Lunsumio® are rash, cytokine release syndrome, pyrexia, fatigue, and headache.
How much does Lunsumio® cost in India?
The cost of Lunsumio in India can vary. In order to procure this follicular lymphoma medication legally, you can Call or WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com.
What are the storage conditions of Lunsumio®?
Store refrigerated at 2-8°C (36-46°F) in the original carton to protect from light. It is not advisable to freeze or shake it.
Is it safe to buy Lunsumio® online in India?
Yes, one can buy Lunsumio online in India at the lowest price from the S S Healthcare if the medicine Lunsumio® is not (yet) registered or available in their country. We can help facilitate the supply of Lunsumio® through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
